Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 1, 2017

BioPharm International

  • BioPharm International-04-01-2017
  • Volume 30
  • Issue 4

Mass Spectrometry System Standardizes Workflows

The X500B QTOF System is the latest solution in SCIEX’s X-Series Quadrupole Time of Flight (QTOF) mass spectrometry (MS) platform.

The X500B QTOF System is the latest solution in SCIEX’s X-Series Quadrupole Time of Flight (QTOF) mass spectrometry (MS) platform. The system was specifically developed to deliver high-resolution standardized workflows for biotherapeutic developers, who are required to fully characterize biologic products in large numbers during the development process.

The X500B QTOF System comes with BioPharmaView Software 2.0, which offers the ability to interpret SWATH 2.0 data independent acquisition on the X500B QTOF System. SWATH acquisition allows for comprehensive peptide mapping data to be acquired in an injection, with high-resolution mass spectrometry and tandem mass spectrometry data for every peptide in the sample. This strategy results in the ability to detect low-abundance peptides and post-translational modifications. 

SCIEX


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.